Search Results for:

Amneal Acquires Kashiv Specialty Pharmaceuticals

On April 5, 2021, Amneal Pharmaceuticals, Inc. (“Amneal”) and Kashiv BioSciences LLC (“Kashiv”) announced that Amneal’s wholly-owned subsidiary, Amneal Pharmaceuticals LLC, has completed its acquisition of a 98% interest in Kashiv’s wholly-owned subsidiary, Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”).  According to the release, Amneal has a portfolio of more than…

Read More

Sanofi to Acquire Kymab for up to $1.45 Billion

Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.  The acquisition…

Read More

Election Day in the US

In observance of Election Day, Goodwin’s US offices are closed on Tuesday, November 3. We encourage everyone in our community to do their civic duty and vote. The BMW blog will be back on Wednesday, November 4.

Read More

Lotus and CKD Announce Biosimilar Collaboration

On September 19, 2020, Lotus Pharmaceutical Co., Ltd. (“Lotus”) and Chong Kun Dang Pharmaceutical Corp. (“CKD”) announced that they have entered into a commercialization agreement in connection with CKD’s biosimilar darbepoetin alfa, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure.  According to Lotus’ press…

Read More

Cadila Pharmaceuticals Launches Rituximab and Bevacizumab Biosimilars

BioSimilars Blog

On July 29, 2020, Cadila Pharmaceuticals announced its launch of Rituximab biosimilar Ritucad for the Indian market. Rituximab is used to treat certain types of blood cancers and rheumatoid arthritis. Ritucad was the Indian pharmaceutical company’s second biosimilar launch in July. On July 22, 2020, Cadila announced the launch of…

Read More

Samsung Bioepis Announces Four-Year Follow-Up Data for its Trastuzumab Biosimilar and 24-Week Interim Results from Phase 3 Trial of its Proposed Ranibizumab Biosimilar

Samsung Bioepis Co., Ltd. announced on Friday that the four-year follow-up data from a Phase 3 study for ONTRUZANT, a biosimilar of HERCEPTIN (trastuzumab), will be presented later this month at the ASCO20 Virtual Scientific Program.  The data are from an ongoing five-year follow-up study assessing the cardiac safety and…

Read More